

Risk of severe cardiotoxicity following treatment with t
randomized and cohort studies of 29,000 women with b

Internal and Emergency Medicine

11, 123-140

DOI: [10.1007/s11739-015-1362-x](https://doi.org/10.1007/s11739-015-1362-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cancer treatment-related cardiac toxicity: prevention, assessment and management. <i>Medical Oncology</i> , 2016, 33, 84.	1.2	27
2	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. <i>Journal of Clinical Oncology</i> , 2016, 34, 4203-4216.	0.8	277
3	The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. <i>Journal of Medical Economics</i> , 2016, 19, 923-927.	1.0	23
4	Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , 2016, 115, 1462-1470.	2.9	23
5	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016, 1, e000073.	2.0	76
6	Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer. <i>American Journal of Therapeutics</i> , 2017, 24, e3-e11.	0.5	18
7	Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 481-490.	2.3	24
8	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 863-871.	1.1	14
9	A Precision Medicine Approach to Improve Cancer Rehabilitation's Impact and Integration with Cancer Care and Optimize Patient Wellness. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2017, 5, 64-73.	0.3	24
10	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
11	Long-term cardiovascular health in adult cancer survivors. <i>Maturitas</i> , 2017, 105, 37-45.	1.0	14
12	ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary. <i>European Heart Journal Supplements</i> , 2017, 19, D370-D379.	0.0	22
13	Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 927-936.	1.1	25
14	Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 173-182.	0.5	26
15	Prevention of Cardiotoxicity in the Cancer Patient. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	0.8	1
16	Targeting the mTOR pathway in breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831771082.	0.8	20
17	Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology. , 2017, , 201-221.		1
18	Cardiovascular Safety in Drug Development and Therapeutic Use. , 2017, , .		9

#	ARTICLE	IF	CITATIONS
19	Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 61-74.	1.1	40
20	Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies. <i>Side Effects of Drugs Annual</i> , 2017, 39, 465-482.	0.6	1
21	Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. <i>Journal of Breast Cancer</i> , 2017, 20, 82.	0.8	18
22	Biological agents in gastrointestinal cancers: adverse effects and their management. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 485-498.	0.6	24
23	Cardiovascular Risk in Cancer Survivors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 47.	0.4	13
24	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. <i>Journal of Thoracic Disease</i> , 2018, 10, S4282-S4295.	0.6	69
25	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1197-1209.	1.0	11
26	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1630-1640.	5.1	237
27	Hypertension in malignancy-an underappreciated problem. <i>Oncotarget</i> , 2018, 9, 20855-20871.	0.8	18
28	Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. <i>Cancer Research</i> , 2018, 78, 6171-6182.	0.4	15
29	Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-15.	1.9	237
30	Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 54-66.	2.0	34
31	Cardio-oncology: an overview on outpatient management and future developments. <i>Netherlands Heart Journal</i> , 2018, 26, 521-532.	0.3	31
32	Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e80-e82.	1.9	8
33	Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab. <i>American Journal of Cardiology</i> , 2019, 123, 1173-1179.	0.7	10
34	Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 599-607.	1.1	16
35	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 1003-1013.	0.5	40
36	Cost-Effectiveness of Adjuvant Trastuzumab Therapy for Early Breast Cancer in Asia: A Systematic Review. <i>Value in Health Regional Issues</i> , 2019, 18, 151-158.	0.5	5

#	ARTICLE	IF	CITATIONS
37	Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology. <i>Stem Cells Translational Medicine</i> , 2019, 8, 758-767.	1.6	5
38	Treatment-Induced Cardiotoxicity in Breast Cancer: A Review of the Interest of Practicing a Physical Activity. <i>Oncology</i> , 2019, 96, 223-234.	0.9	27
39	Arterial hypertension in patients under antineoplastic therapy. <i>Journal of Hypertension</i> , 2019, 37, 884-901.	0.3	23
40	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. <i>Annals of Oncology</i> , 2019, 30, 418-423.	0.6	66
41	Peripherally inserted central catheter-related thrombosis rate in modern vascular access era when insertion technique matters: A systematic review and meta-analysis. <i>Journal of Vascular Access</i> , 2020, 21, 45-54.	0.5	75
42	New Cardiac Abnormalities After Radiotherapy in Breast Cancer Patients Treated With Trastuzumab. <i>Clinical Breast Cancer</i> , 2020, 20, 246-252.	1.1	6
43	Hypertension management in cardio-oncology. <i>Journal of Human Hypertension</i> , 2020, 34, 673-681.	1.0	24
44	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 2290-2309.	2.9	62
45	Effect at One Year of Adjuvant Trastuzumab for HER2+ Breast Cancer Combined with Radiation or an Anthracycline on Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 125, 1906-1912.	0.7	0
46	Obesity and breast cancer. , 2020, , 201-208.		0
47	Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 978.	3.4	65
48	Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis. <i>CJC Open</i> , 2021, 3, 1372-1382.	0.7	28
49	RADIATION-INDUCED TOXICITY IN BREAST CANCER PATIENTS TREATED WITH TRASTUZUMAB-BASED CHEMOTHERAPY. <i>Siberian Journal of Oncology</i> , 2021, 20, 91-98.	0.1	1
50	Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension, 2017, 14, 6-20.	0.1	8
51	Six versus 12 months adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	1.3	11
52	Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients. , 2020, , 1-25.		0
53	CARDIOVASCULAR COMPLICATIONS OF ANTITUMOR THERAPY FOR BREAST CANCER: DIAGNOSIS, PREVENTION AND TREATMENT. <i>Siberian Journal of Oncology</i> , 2021, 20, 138-148.	0.1	1
54	Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study. <i>Gland Surgery</i> , 2020, 9, 2079-2090.	0.5	15

#	ARTICLE	IF	CITATIONS
55	Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients. , 2020, , 765-789.		0
56	Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling. Iranian Journal of Basic Medical Sciences, 2020, 23, 865-870.	1.0	2
57	Cardiotoxicity of chemotherapy and targeted agents. American Journal of Cancer Research, 2021, 11, 1132-1147.	1.4	3
58	Cardiac Function Checkup During Trastuzumab Therapy Among Patients With Breast Cancer. Clinical Breast Cancer, 2022, , .	1.1	0
59	Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers, 2022, 14, 1218.	1.7	2
60	Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance. Cardiology Research and Practice, 2022, 2022, 1-14.	0.5	5
61	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian Heart Journal, 2022, , 6-79.	0.2	6
62	Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study. Frontiers in Oncology, 2021, 11, 744609.	1.3	2
64	Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. Cancers, 2022, 14, 3003.	1.7	3
65	Cardiovascular Imaging in Cardio-Oncology. Heart Failure Clinics, 2022, 18, 455-478.	1.0	2
66	Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-9.	0.7	6
67	Cardiotoxicity among socioeconomically marginalized breast cancer patients. Breast Cancer Research and Treatment, 0, , .	1.1	0
69	Risk Prediction Models for Myocardial Dysfunction and Heart Failure in Patients with Current or Prior Cancer. Current Oncology Reports, 2023, 25, 353-367.	1.8	1
71	Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. European Journal of Cancer, 2023, 190, 112885.	1.3	5